By Fineline Cube 
Hasten Biopharmaceutical Co., Ltd. and Everest Medicines Limited (HKG: 1952) announced two strategic agreements: a commercialization services deal for six mature products and an exclusive licensing agreement for Lerodalcibep, a third‑generation PCSK9 inhibitor, in Greater China. Everest will pay $29 million upfront and up to $339 million in total milestones plus royalties.
Transaction Structure
| Agreement Type | Scope | Financial Terms |
|---|---|---|
| Commercialization Services | Everest to commercialize 6 Hanssen Bio products (critical care, CV, metabolic) in Mainland China | Service fees undisclosed |
| Lerodalcibep Licensing | Exclusive rights for development, registration, and commercialization in Greater China | • Upfront: $29 M • Development/regulatory milestones: up to $30 M • Sales milestones: up to $280 M • Tiered royalties on net sales |
| Total Potential Value | — | $339 million (excluding royalties) |
| Payment Method | Combination of internal resources and external financing | — |
Lerodalcibep Drug Profile
| Attribute | Details |
|---|---|
| Mechanism | Third‑generation PCSK9 inhibitor small‑molecule fusion protein |
| Indication | Hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) |
| Administration | Once‑monthly, small‑volume subcutaneous injection |
| Origin | Developed by LIB Therapeutics (US private company) |
| Hanssen Acquisition | Hasten acquired Greater China rights in Sept 2023 for >$300 million |
| Differentiation | More convenient storage and portability vs. currently approved PCSK9 inhibitors |
Market Opportunity
| Metric | Value | Implication |
|---|---|---|
| China Hypercholesterolemia Patients | > 100 million adults (2024) | <10% achieve LDL‑C targets |
| China PCSK9 Market | ¥2‑3 billion (≈ US$280‑420 M) | Dominated by Repatha and Praluent |
| Lerodalcibep Peak Sales (China) | ¥1.5‑2.5 billion (≈ US$210‑350 M) by 2032 | 20‑30% share with monthly dosing advantage |
| Reimbursement Strategy | Target NRDL inclusion by 2027 with competitive pricing | Accelerates hospital adoption |
Strategic Implications
- For Everest: Expands high‑value CV/metabolic portfolio; leverages existing commercial platform for rapid market penetration; adds innovative PCSK9 inhibitor to pipeline.
- For Hasten: Monetizes Lerodalcibep rights; generates cash flow to fund broader pipeline; maintains product development capabilities.
- For Patients: Once‑monthly dosing improves convenience and adherence compared to biweekly competitors; addresses major compliance barrier in LDL‑C management.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding milestone achievements, commercial launch timelines, and market penetration. Actual results may differ due to regulatory delays, competitive responses, or financing constraints.-Fineline Info & Tech